Search

Your search keyword '"Senna G"' showing total 731 results

Search Constraints

Start Over You searched for: Author "Senna G" Remove constraint Author: "Senna G"
731 results on '"Senna G"'

Search Results

1. Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study

2. Diagnosis and Management of Allergic Rhinitis in Asthmatic Children

3. Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

4. Organization, Clinical and Management Indicators on the First Year of Activity of an Outpatient Clinic Dedicated to the Diagnosis and Treatment of Severe Asthma in Italy

5. Uncontrolled Asthma: Unmet Needs in the Management of Patients

6. Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry

7. New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

9. Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY Survey

13. Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials

18. A hierarchical cluster analysis of the psycological impact of the COVID-19 pandemic on Italian severe asthma patients

19. Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma

20. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

21. Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry

23. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

25. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

28. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

29. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper (vol 12, 100080, 2020)

30. Severe asthma: One disease and multiple definitions

31. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

34. Frequency of tiotropium bromide use and clinical features of patients with severe asthma in a real-life setting: Data from the severe asthma network in Italy (sani) registry

35. A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

36. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper

37. Characteristics and treatment regimens across ERS SHARP severe asthma registries

38. Minimal clinically important difference for asthma endpoints: An expert consensus report

39. Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

40. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

45. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

46. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper

49. Characteristics and treatment regimens across ERS SHARP severe asthma registries

Catalog

Books, media, physical & digital resources